Mutual of America Capital Management LLC Makes New $700,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Mutual of America Capital Management LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 28,961 shares of the company's stock, valued at approximately $700,000.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after buying an additional 807 shares in the last quarter. Stonekeep Investments LLC increased its holdings in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock valued at $410,000 after purchasing an additional 882 shares in the last quarter. Principal Securities Inc. raised its position in Hims & Hers Health by 48.2% in the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company's stock valued at $74,000 after purchasing an additional 1,002 shares during the last quarter. Cadent Capital Advisors LLC boosted its stake in Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company's stock worth $1,745,000 after purchasing an additional 1,060 shares in the last quarter. Finally, Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research firms recently issued reports on HIMS. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. TD Cowen reissued a "buy" rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $37.23.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,259 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total value of $234,102.75. Following the completion of the transaction, the insider now directly owns 184,947 shares in the company, valued at approximately $5,964,540.75. The trade was a 3.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at approximately $2,885,801.88. The trade was a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,062,011 shares of company stock valued at $36,892,724. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Down 4.5 %

Shares of Hims & Hers Health stock traded down $1.61 during trading on Monday, reaching $34.34. 29,209,907 shares of the company were exchanged, compared to its average volume of 13,247,102. The business has a 50-day moving average price of $37.83 and a 200-day moving average price of $27.73. The firm has a market capitalization of $7.63 billion, a price-to-earnings ratio of 78.04 and a beta of 1.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.